By Professor Dedee Frances Murrell

Journal articles

Murrell DF; Daneshpazhooh M, 2024, 'Impairment of sexual function in patients with pemphigus', Journal of the European Academy of Dermatology and Venereology, 38, pp. 643 - 644, http://dx.doi.org/10.1111/jdv.19882

Navarrete-Dechent C; Ashique KT; Ingram JR; Rudnicka L; Gilaberte Y; Ring J; Murrell DF; Elston D; Thiers BH, 2024, 'The road to publication: Advice from journal editors', Journal of the American Academy of Dermatology, 90, pp. 707 - 710, http://dx.doi.org/10.1016/j.jaad.2023.11.038

Labbouz S; Khan S; Gohara M; Lucas J; Sarkar R; Murrell DF; Dodiuk-Gad RP, 2024, 'Meeting report: Women’s Dermatology Society Forum at the 25th World Congress of Dermatology, Singapore, 2023', International Journal of Women's Dermatology, 10, http://dx.doi.org/10.1097/JW9.0000000000000125

Caux F; Patsatsi A; Karakioulaki M; Antiga E; Baselga E; Borradori L; Caproni M; Cardones AR; Chandran NS; Dräger S; Drenovska K; Goebeler M; Günther C; Hofmann SC; Ioannides D; Joly P; Marinović B; Mariotti EB; Marzano AV; Morel KD; Murrell DF; Prost C; Sárdy M; Setterfield J; Skiljevic D; Uzun S; Vassileva S; Zambruno G; Schmidt E, 2024, 'S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology', Journal of the European Academy of Dermatology and Venereology, http://dx.doi.org/10.1111/jdv.19880

Guttman-Yassky E; Bahadori L; Brooks L; Clark KL; Grindebacke H; Ho CN; Katial R; Pham TH; Walton C; Datto CJ, 2023, 'Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1211 - e1214, http://dx.doi.org/10.1111/jdv.19195

Kircik LH; Alonso-Llamazares J; Bhatia N; Bukhalo M; Devani AR; Draelos ZD; Dubois J; Gooderham MJ; Kempers SE; Lain E; Lee M; Moore A; Murrell DF; Papp KA; Pariser DM; Sinclair R; Zirwas M; Burnett P; Higham RC; Krupa D; Berk DR, 2023, 'Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study', British Journal of Dermatology, 189, pp. 392 - 399, http://dx.doi.org/10.1093/bjd/ljad182

Yale M; Dunn P; Strong R; Davies I; Gallu L; Joly P; Murrell DF; Werth VP; Payne AS, 2023, 'The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid', Journal of Investigative Dermatology, 143, pp. 1868 - 1871, http://dx.doi.org/10.1016/j.jid.2023.03.1673

Wilson BN; Shah R; Sun MD; Diaz AF; Murrell DF; Murase JE, 2023, 'Evaluation of skin of color publication trends over the past 2 decades in the Journal of the American Academy of Dermatology', Journal of the American Academy of Dermatology, 89, pp. 614 - 616, http://dx.doi.org/10.1016/j.jaad.2023.05.036

Singh S; Kirtschig G; Anchan VN; Chi CC; Taghipour K; Boyle RJ; Murrell DF, 2023, 'Interventions for bullous pemphigoid', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD002292.pub4

Wang MA; Wilson A; Murrell DF, 2023, 'A Review of the Scoring and Assessment of Keratosis Pilaris', Skin Appendage Disorders, 9, pp. 241 - 251, http://dx.doi.org/10.1159/000529487

Mosallaei D; Murrell DF; Grant-Kels JM, 2023, 'Dermatoethics: Nepotism in dermatology residencies', Journal of the American Academy of Dermatology, 89, pp. 193 - 194, http://dx.doi.org/10.1016/j.jaad.2022.01.011

Silverberg JI; Bissonnette R; Kircik L; Murrell DF; Selfridge A; Liu K; Ahluwalia G; Guttman-Yassky E, 2023, 'Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1366 - 1374, http://dx.doi.org/10.1111/jdv.18914

Patel NJ; Jayne DRW; Merkel PA; Bekker P; Zhang Y; McDowell PJ; Johal J; Heaney LG; Murrell D; Stone MN; Yue H; Stone JH, 2023, 'The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial', The Lancet Rheumatology, 5, pp. e413 - e421, http://dx.doi.org/10.1016/S2665-9913(23)00131-5

Murrell D; L. Bruckner A; Sprecher E; Kiritsi D; Maher L; Cunningham T; Kern JS, 2023, 'BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study', British Journal of Dermatology, 188, http://dx.doi.org/10.1093/bjd/ljad113.144

Teng J; Paller AS; Bruckner AL; Murrell DF; Mellerio JE; Bodemer C; Martinez AE; Lugo-Somolinos A; Sprecher E; Laimer M; Wally V; Chan YM; Lin SY; Spellman M; Bauer JW, 2023, 'Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial', Journal of Drugs in Dermatology, 22, pp. 599 - 604, http://dx.doi.org/10.36849/JDD.7108

Murrell DF; Teng JMC; Guenthner S; Marathe K; Kempers S; Eads K; Castelo-Soccio L; Mendelsohn AM; Raiz J; Bunick CG, 2023, 'Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis', Clinical and Experimental Dermatology, 48, pp. 623 - 630, http://dx.doi.org/10.1093/ced/llad033

Cowan TL; Ho G; Daniel BS; Murrell DF, 2023, 'Use of a hybrid teledermatology model in an Australian tertiary hospital during the COVID-19 pandemic', JAAD International, 11, pp. 33 - 34, http://dx.doi.org/10.1016/j.jdin.2022.03.016

Lee H; Cowan TL; Daniel BS; Murrell DF, 2023, 'A review of JAK and IL-23 inhibitors to treat vitiligo', Australasian Journal of Dermatology, 64, pp. 204 - 212, http://dx.doi.org/10.1111/ajd.14001

Wilson A; Tariq Khan M; Murrell DF, 2023, 'Median canaliform nail dystrophy in a 2-year-old boy: Case report and review of the literature', Pediatric Dermatology, 40, pp. 511 - 518, http://dx.doi.org/10.1111/pde.15181

Aung T; Noakes R; Murrell DF; Daniel BS; Kelati A, 2023, 'Primary cutaneous amyloidosis: A review of the available studies and gaps in data', Australasian Journal of Dermatology, 64, pp. e121 - e124, http://dx.doi.org/10.1111/ajd.14012

Johal JS; Cowan TL; Murrell DF, 2023, 'Evaluating the nature and prevalence of glucocorticoid-induced type 2 diabetes mellitus in patients with autoimmune bullous diseases', Clinical and experimental dermatology, 48, pp. 448 - 452, http://dx.doi.org/10.1093/ced/llac137

Williams TG; Hackett LM; Lam PH; Stitz DJ; Al-Housni H; Murrell DF; Murrell GAC, 2023, 'Fibrillar matrix, Echogenicity, Contour, Thickness, and Suture (FECTS) vs. Global: A comparison of 2 scales developed to assess ultrasound images post rotator cuff repair', Journal of Shoulder and Elbow Surgery, 32, pp. 713 - 728, http://dx.doi.org/10.1016/j.jse.2022.10.035

Tully JM; Murase JE; Grant-Kels JM; Murrell DF, 2023, 'Gender Equity in Medicine and Dermatology in the United States: The Long Road Traveled and the Journey ahead', Dermatologic Clinics, 41, pp. 265 - 278, http://dx.doi.org/10.1016/j.det.2022.08.007

Xie D; Bilgic A; Abu Alrub N; Dicle Ö; Murrell DF, 2023, 'Clinical manifestations of alopecia in autoimmune blistering diseases: A cross-sectional study', JAAD International, 10, pp. 6 - 13, http://dx.doi.org/10.1016/j.jdin.2022.08.025

Wilson A; Cowan TL; Rivero ADL; Murrell DF, 2023, 'The dangers of social media: patients with atopic dermatitis ceasing their basic treatment', Clinical and Experimental Dermatology, 48, pp. 142 - 143, http://dx.doi.org/10.1093/ced/llac056

COWAN T; ABU ALRUB N; WİLSON A; MAKHİJA M; MURRELL D, 2023, 'Eksfolyatif keilit tedavisinde tildrakizumab', Mucosa, 6, pp. 19 - 21, http://dx.doi.org/10.33204/mucosa.1209480

Murrell DF; Joly P; Werth VP; Laws E; Mannent LP; Beazley B; Dubost-Brama A; Shabbir A, 2023, '307 The study design of a trial of dupilumab in adult patients with bullous pemphigoid (BP): LIBERTY-BP ADEPT', British Journal of Dermatology, 188, http://dx.doi.org/10.1093/bjd/ljac140.007

Hundt JE; Sadik CD; van Beek N; Busch H; Caux F; Goebeler M; Hammers CM; Hartmann K; Hashimoto T; Ibrahim S; Kasperkiewicz M; Murrell DF; Recke A; Rose C; Schumacher N; Shimanovich I; Sitaru C; Terheyden P; Thaçi D; Ludwig RJ; Schmidt E, 2023, 'A life for autoimmune blistering diseases: in memoriam Detlef Zillikens', Frontiers in Immunology, 14, http://dx.doi.org/10.3389/fimmu.2023.1291590

Koszegi B; Stone C; Murrell DF, 2023, 'Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia', Frontiers in Medicine, 10, http://dx.doi.org/10.3389/fmed.2023.1149742

Patsatsi A; Daneshpazhooh M; Tavakolpour S; Mahmoudi H; Murrell DF, 2023, 'Editorial: Challenges of COVID-19 in dermatology patients on immunosuppression: risk, outcome, vaccination and beyond, volume II', Frontiers in Medicine, 10, http://dx.doi.org/10.3389/fmed.2023.1268285

Kern JS; Sprecher E; Fernandez MF; Schauer F; Bodemer C; Cunningham T; Löwe S; Davis C; Sumeray M; Bruckner AL; Murrell DF, 2023, 'Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study', British Journal of Dermatology, 188, pp. 12 - 21, http://dx.doi.org/10.1093/bjd/ljac001

Rodriguez R; Sivesind TE; Murrell D; Dellavalle RP, 2023, 'From the Cochrane Library: Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus', JMIR Dermatology, 6, http://dx.doi.org/10.2196/46812

Huang C; Bullpitt P; Nabarrro M; Murrell DF, 2023, 'Practice Dilemma: Expanding Melanonychia in the Paediatric Setting', Skin Appendage Disorders, 9, pp. 58 - 60, http://dx.doi.org/10.1159/000526102

Johal J; Cowan T; Bilgic A; Bozca B; Enli S; Yang B; Daneshpazhooh M; Boziou M; Patsatsi A; Mundin C; Quizon M; Kakuta R; Takahashi H; Wilson A; Zeng F; Murrell D, 2023, '390 Examining the risk factors for worsened glucocorticoid morbidity in a prospective, multicentre, international study of patients with autoimmune blistering diseases', Journal of Investigative Dermatology, 143, pp. S67 - S67, http://dx.doi.org/10.1016/j.jid.2023.03.396

Wang MA; Wilson A; Daniel B; Rivero ADL; Martin L; Kern JS; Murrell D, 2023, '396 A novel investigator global assessment score for the evaluation of keratosis pilaris', Journal of Investigative Dermatology, 143, pp. S68 - S68, http://dx.doi.org/10.1016/j.jid.2023.03.402

Tada Y; Takeoka S; Spelman L; Murrell D; Chu C; Chung W; Wu J; Zoob P; Bosman K, 2023, '459 Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis', Journal of Investigative Dermatology, 143, pp. S79 - S79, http://dx.doi.org/10.1016/j.jid.2023.03.465

Joly P; Patel HV; Cella RR; Kephart L; Murrell D, 2023, '639 Design of marigold-bp: A phase 2/3 study of nipocalimab in adults with moderate to severe bullous pemphigoid', Journal of Investigative Dermatology, 143, pp. S109 - S109, http://dx.doi.org/10.1016/j.jid.2023.03.646

Bai H; Lin G; Kantor J; Elston D; Grant-Kels JM; Murrell DF; Murase JE, 2023, 'Dermatology Journal Advisory Boards and Editorial Independence', JAAD International, http://dx.doi.org/10.1016/j.jdin.2023.08.001

Schmidt E; Diaz LA; Amagai M; Murrell DF, 2023, 'Detlef Zillikens, 1958-2022', Journal of Investigative Dermatology, 143, pp. 7 - 8, http://dx.doi.org/10.1016/j.jid.2022.11.001

Keller Rosenthal N; Boucher D; Murrell DF, 2022, 'The efficacy of adding oral sodium cromoglycate to stable treatment for controlling bullous pemphigoid-related pruritus: A retrospective study', Frontiers in Medicine, 9, http://dx.doi.org/10.3389/fmed.2022.1051804

So JY; Fulchand S; Wong CY; Li S; Nazaroff J; Gorell ES; de Souza MP; Murrell DF; Teng JM; Chiou AS; Tang JY, 2022, 'A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex', Orphanet Journal of Rare Diseases, 17, http://dx.doi.org/10.1186/s13023-022-02433-3

Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF, 2022, 'A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa', Orphanet Journal of Rare Diseases, 17, http://dx.doi.org/10.1186/s13023-022-02461-z

Vermeer MCSC; Al-Shinnag M; Silljé HHW; Gaytan AE; Murrell DF; McGaughran J; Melbourne W; Cowan T; van den Akker PC; van Spaendonck-Zwarts KY; van der Meer P; Bolling MC, 2022, 'A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradation', British Journal of Dermatology, 187, pp. 1045 - 1048, http://dx.doi.org/10.1111/bjd.21832

Mazaherpour E; Kianfar N; Dasdar S; Sedaghat M; Seyrafi H; Balighi K; Saberi F; Nili A; Farimani Z; Azar PM; Mahmoodi H; Murrell DF; Daneshpazhooh M, 2022, 'Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab-treated and rituximab-naïve patients', Dermatologic Therapy, 35, http://dx.doi.org/10.1111/dth.15902

Ho G; Gibson M; Kazemikhoo N; Murrell DF, 2022, 'Long-term follow-up of epidermolysis bullosa in real practice shows stability of the Epidermolysis Bullosa Disease Activity and Scarring Index and improvement with some off-label therapies', JAAD International, 9, pp. 105 - 107, http://dx.doi.org/10.1016/j.jdin.2022.07.008

Lee BWH; Taylor SF; Gal A; Murrell DF; Coroneo MT, 2022, 'Sebaceous cell carcinoma presenting as ocular Marjolin ulcer following immunosuppression for a chemical burn', Canadian Journal of Ophthalmology, 57, pp. e206 - e208, http://dx.doi.org/10.1016/j.jcjo.2022.02.023

Zeng FAP; Wilson A; Sheriff T; Murrell DF, 2022, 'Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review', JAAD International, 9, pp. 33 - 43, http://dx.doi.org/10.1016/j.jdin.2022.07.005

Teng JMC; Bunick CG; Guenthner S; Murrell DF; Marathe K; Kempers S; Eads K; Mendelsohn AM; Raiz J; Tavakkol A; Castelo-Soccio L, 2022, 'The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis', Journal of the American Academy of Dermatology, 87, pp. 1455 - 1458, http://dx.doi.org/10.1016/j.jaad.2022.07.028

Zeng FAP; Murrell DF, 2022, 'Bullous pemphigoid—What do we know about the most recent therapies?', Frontiers in Medicine, 9, http://dx.doi.org/10.3389/fmed.2022.1057096

Bilgic A; Murrell DF, 2022, 'Designing the Future of Dermatology and Venereology', EMJ Dermatology, pp. 18 - 19, http://dx.doi.org/10.33590/emjdermatol/10176803

Back to profile page